Overview

Therapeutic Effect of Isoladine Maleate on Small Intestinal Mucosal Injury Associated With NSAIDS in Population

Status:
Not yet recruiting

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

All patients who met the inclusion criteria and agreed to participate in the study underwent baseline capsule endoscopy. Patients with intestinal mucosal injury detected during the initial capsule endoscopy were randomly divided into isoladin maleate group or magnesium aluminum carbonate control group using computer-generated random numbers. Patients in the isoladine maleate group received 4 mg isoladine maleate (Gesellon, Japan) every morning for 4 weeks (or 8 weeks, duration to be determined); Magnesium aluminum carbonate control group received 1 g magnesium aluminum carbonate every morning, afternoon and evening for 4 weeks (or 8 weeks, course to be determined). After treatment, capsule endoscopy was performed again to evaluate the healing of intestinal mucosa.

Phase:

Phase 4

Details

Lead Sponsor:

Lee's Pharmaceutical Limited

Treatments:

Hydrotalcite
Irsogladine